



Dr. Barbara Laughon, Ph.D.

Dr. Barbara Laughon is Senior Scientist for TB Drug Development Partnerships in the Office of the Director, Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. She is the primary NIH liaison with the Eli Lilly Not-for-Profit Partnership for TB Early Phase Drug Discovery. She also serves as Chair of the Scientific Advisory Committee to the Global Alliance for TB Drug Development (TB Alliance) and was one of the original founding stakeholders of this public-private partnership. She is an active participant in the STOP-TB Partnership serving in working groups on New Drugs and TB/HIV co-infection.

Dr. Laughon came to NIH in 1989 as a Senior Scientist/Microbiologist in the Developmental Therapeutics Program of the Division of AIDS, NIAID assuming the responsibility for an extramural program of laboratory-based grants and contracts to discover and develop new therapies for AIDS-related opportunistic infections. She has served as a Section Chief, and most recently as Chief of the Complications and Co-Infections Research Branch in the Therapeutics Research Program of the Division of AIDS for 10 years. During this time, she was responsible for a large research portfolio in grants, cooperative agreements, and contracts focused upon preclinical and clinical anti-infective drug development for tuberculosis and other infectious complications of AIDS. Throughout her career at NIH, she has contributed to developing yearly research plans with the Office of AIDS Research, NIH, PEPFAR, and within the NIAID for international and domestic research on hepatitis C and tuberculosis.

Prior to joining the NIAID, Dr. Laughon was an assistant professor of medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her research involved the pathophysiology and biochemistry of *Clostridium difficile* antibiotic-associated colitis and clinical research on the prevalence of enteric pathogens among homosexual men hospitalized with AIDS and/or participating in a longitudinal Multicenter AIDS Cohort Study. Dr. Laughon also contributed as an adjunct assistant professor in the Department of Immunology and Infectious Diseases at Johns Hopkins University School of Hygiene and Public Health.

Dr. Laughon received her Masters of Science and Doctor of Philosophy degree in microbiology from the Anaerobe Laboratory at Virginia Polytechnic Institute and State University with a dissertation on the ultrastructure and biochemistry of anaerobic spirochetes. As a postdoctoral scholar at the University of Michigan, she characterized the role of anaerobic bacteria in the pathogenesis of advanced periodontal disease. She is a fellow of the Infectious Diseases Society of America, a member of the American Society for Microbiology and has published over 50 scientific articles, invited papers and abstracts.